Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Dehydroabietinol (CAS No.: 3772-55-2) is a typical rosin diterpene compound, widely found in resins of pine plants. As an important member of diterpenes in natural products, dehydroquinol, due to its unique structure and diverse biological activities, has attracted widespread attention in pharmacological research in recent years. Especially in immunomodulatory and antimicrobial activity, dehydroquinols show significant potential, emerging as a candidate for studying immune-mediated diseases and anti-infective therapies.
This review aims to systematically summarize the chemical structure and physicochemical properties of dehydrofiranol, plant origin and extraction methods, pharmacological activity and mechanism of action, druggability evaluation and pharmacokinetic characteristics, and to explore its potential value and future development directions in clinical applications, providing comprehensive reference materials for researchers in related fields.
Dehydroquinols belong to the rosin diterpene class, with a molecular formula of C20H30O and a molecular weight of 286.4590. Its structure is based on the tricyclic rosin skeleton and contains a hydroxyl functional group, imparting certain polarity and reactivity to it. The chemical structure characteristics of dehydrofiranol give it strong lipophilicity in intermolecular interactions.
In terms of physicochemical properties, dehydroquinol's LogP value is 5.6412, indicating strong hydrophobicity. This property facilitates its penetration of cell membranes but also limits its water solubility (only 0.0008), which may affect its bioavailability. The topological pole surface area (TPSA) of dehydroquinol is 20.2300, and a lower pole surface area is usually associated with better cell membrane permeability. Additionally, dehydrofigrin has a high blood-brain barrier penetration capability, giving it potential application value in research on central nervous system-related diseases. In terms of safety, dehydrofilenol did not show hERG channel inhibition, and Ames mutagenic test results were zero, indicating low risk in terms of cardiotoxicity and genotoxicity.
Dehydroquinol is mainly found in the resins and leaves of pine family plants, especially in the rosin of conifers such as Picea spp., Abies spp., and Pinus spp., which are relatively abundant. Rosin, as a traditional natural resin, has a long history and is widely used in industry and medicine. Its composition is complex, and dehydroquinol is one of the important active components.
Common methods for extracting dehydroquinol include solvent extraction, liquid-liquid partitioning, and chromatographic purification. Traditional extraction solvents mostly use organic solvents such as ethanol, methanol, or ethyl acetate, which are extracted by reflux or ultrasound to improve extraction efficiency. The extract is further purified using silica gel column chromatography, reversed-phase high-performance liquid chromatography (RP-HPLC), and other techniques to obtain high-purity dehydrogen-butane alcohol. In recent years, supercritical CO2 extraction technology, due to its green environmental friendliness and efficient selectivity, has gradually been applied to the extraction of dehydroquinol, significantly improving extraction purity and yield.
Research on the pharmacological activity of dehydrofiranol mainly focuses on its immunomodulatory and antimicrobial effects. It exhibited inhibitory activity against the immune-related kinase SYK (Spleen Tyrosine Kinase), with an IC50 value of 46.4 μM. SYK acts as a key kinase in immune cell signal transduction, participating in signal transduction mediated by B cell receptors (BCR) and Fc receptors, regulating inflammatory responses and immune cell activation. Dehydroxenol demonstrates potential immunomodulatory functions by inhibiting SYK kinase activity, making it suitable for research on immune-mediated diseases such as autoimmune and inflammatory disorders.
In addition, dehydroquinol also demonstrates broad effects in antimicrobial activity. Its targets involve multiple key molecules, including:
The diversity of these targets suggests that dehydroquinol may exert its antimicrobial activity through multi-target synergistic action, covering various pathogens such as bacteria and fungi, demonstrating broad anti-infectivity potential.
The mechanism of action of dehydrofiranol is mainly based on its regulation of immune signaling pathways and key microbial enzymes. As an inhibitor of SYK kinase, dehydroquinols block SYK tyrosine kinase activity, interfere with signal transduction by B cells and other immune cells, suppress the release of inflammatory mediators and the overactivation of immune cells, thereby reducing immune-mediated tissue damage.
In terms of antimicrobial effects, dehydrofiranol exerts its effects through a multi-target mechanism:
Immune regulatory targets: By regulating the TLR4-MyD88 signaling pathway, dehydrofenol can modulate innate immune responses and enhance the host's ability to recognize and clear pathogens.
Bacterial and fungal targets: Dehydroxucanol inhibits the activity of key enzymes such as DHFR, ERG11, CYP51, and FKS1, blocks pathogen metabolism and cell membrane synthesis, and inhibits their growth and reproduction.
DNA replication and cell wall synthesis targets: By acting on GYRB and PBP2, dehydroquinol affects bacterial DNA replication and cell wall synthesis, further enhancing its antibacterial effect.
Antimicrobial peptide regulation: Dehydrofiranol modulates DEFB1 to promote host antimicrobial peptide expression, enhancing innate immune defense.
These multi-target synergistic mechanisms provide a theoretical basis for the application of dehydrofiranol in complex infection environments and offer important clues for its development as a novel anti-infective drug.
The druggability parameters of dehydroxenol indicate that it has certain potential for drug development. Its relatively high LogP value (5.6412) indicates that the molecule is highly hydrophobic, which facilitates cell membrane penetration, but may result in extremely poor water solubility (0.0008), posing challenges for oral bioavailability. Low TPSA (20.2300) and high blood-brain barrier penetration capacity suggest that dehydrofenol has potential advantages in treating central nervous system diseases.
In terms of safety, dehydrofenol did not show hERG channel inhibition, reducing the risk of cardiotoxicity; The Ames test was negative, indicating no significant mutagenicity, providing a solid safety foundation for its clinical application.
Currently, pharmacokinetic studies on dehydrogenols are limited, but data suggest that metabolism in the body may involve hepatic enzyme systems, and high hydrophobicity may lead to strong tissue accumulation. Future studies on in vivo absorption, distribution, metabolism, and excretion (ADME) are needed to clarify its pharmacokinetic characteristics and dosage form optimization strategies.
Dehydroquintanol's activity in immunomodulatory and antimicrobial fields offers broad clinical application prospects. As a SYK kinase inhibitor, dehydrogenolol is expected to be used in the treatment of autoimmune diseases (such as rheumatoid arthritis and systemic lupus erythematosus) and inflammatory diseases, reducing pathological inflammation by modulating immune signaling pathways.
Its broad-spectrum antimicrobial activity, covering various pathogens such as bacteria and fungi, especially its potential inhibitory effect on resistant strains, makes it an emerging candidate for anti-infective treatment. In addition, dehydrofenol's excellent blood-brain barrier penetration ability offers possibilities for treating central nervous system infections and related diseases.
However, bioavailability issues caused by dehydroxuitol's low water solubility and hydrophobicity, as well as the lack of systematic preclinical and clinical research, remain major obstacles in its development. Future research should focus on:
Through multidisciplinary collaboration, dehydroxutonol is expected to become an important player in the development of natural product drugs.
As a rosin diterpene with its unique chemical structure and multi-target pharmacological activity, dehydroquinol, demonstrates broad application potential in immunomodulatory and antimicrobial fields. Its inhibitory effect on SYK kinase offers new approaches for the treatment of immune-mediated diseases, while its multi-target antimicrobial mechanism offers valuable lead compounds for anti-infective drug development.
Although dehydroxubutyl alcohol still faces many challenges in druggability and clinical application, with the ongoing advancement of extraction and purification technologies, drug delivery systems, and pharmacological mechanism research, dehydroxutenol is expected to play an important role in future natural product drug development. Future research should focus on systematic pharmacokinetic studies and preclinical validation to promote clinical translation and ultimately benefit patients.
